Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. (CompareAcute)
Fractional Flow Reserve Guided Primary Multivessel Percutaneous Coronary Intervention to Improve Guideline Indexed Actual Standard of Care for Treatment of ST-elevation Myocardial Infarction in Patients With Multivessel Coronary Disease
The Compare-Acute trial is a prospective randomised trial in patients with multivessel disease, who are admitted into hospital with a ST-elevation Myocardial Infarction. The purpose of the study is to compare a FFR guided multivessel PCI taking place during the primary PCI with a primary PCI of the culprit vessel only.
Patients will be enrolled after successful revascularisation of the culprit vessel. Patients that have at least one lesion with a diameter of stenosis of more than 50% on visual estimation, feasible (operators judgement) for treatment with PCI in a non-infarct related artery, will be randomised either to the FFR guided complete revascularisation arm or staged revascularisation by proven ischemia or persistence of symptoms of angina.
Approximately 885 patients will be entered in the study.
Study hypothesis: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Background of the study: At the moment the general opinion is divided over the way the non culprit lesions in patients presenting with STEMI should be treated. While the previous guidelines stead that these lesions should be treated in a second time ( ie not during the primary intervention) the actual guidelines do not touch this argument. The reason is that the studies where the previous guidelines were based are old. Meanwhile small sized randomised trials from EU region have proven favourable outcomes with NON infarct related artery during the primary procedure while registers (non randomised trials) from USA still recommend the staged treatment. For this reason we have decided to perform a randomised study to address this issue incorporating the state of the art diagnosis and treatment, as well as the new medical therapy and PCI techniques.
Objective of the study: FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines
Study design: Prospective, 1: 2 randomisation. FFR guided revascularisation during primary PCI (1) versus following actual guidelines (2)
Study population: All STEMI patients between 18-85 years who will be treated with primary PCI in < 12 h (more than 12 hr if persisting pain allowed) after the onset of symptoms and have at least one stenosis of >50% in a non-IRA judged feasible for treatment with PCI.
Intervention (if applicable): FFR-guided complete percutaneous revascularisation of all flow-limiting stenoses in the non-IRA performed within the same procedure as the primary PCI or within the same hospitalisation will improve clinical outcomes compared to the staged revascularisation, guided by prove of ischemia or clinical judgment, as recommended from the guidelines
Primary study parameters/outcome of the study: Composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Stroke (MACCE) at 12 months
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Bad Krozingen, Duitsland, 79189
- Herz-Zentrum Bad Krozingen
-
Bad Segeberg, Duitsland, 23795
- Herzzentrum Bad Segeberger Klinik
-
Bremen, Duitsland, 28277
- Klinikum Links der Weser
-
Ingolstadt, Duitsland, 85049
- Medizinische Klinik IV
-
Rostock, Duitsland, 18057
- Medical University Rostock
-
-
-
-
-
Budapest, Hongarije
- Gottsegen György Országos Kardiológiai Intézet
-
Nyíregyháza, Hongarije
- Szabolcs - Szatmár - Bereg County Hospitals and University Teaching Hospital
-
Szeged, Hongarije
- Szent-Györgyi Albert Klinika
-
Zalaegerszeg, Hongarije
- Zala Megyei Kórház
-
-
-
-
-
Arnhem, Nederland
- Rijnstate Hospital
-
Groningen, Nederland
- University Medical Center Groningen
-
Heerlen, Nederland
- Atrium MC Parkstad
-
Maastricht, Nederland
- Maastricht Universitair Medical center
-
Rotterdam, Nederland, 3079DZ
- Maasstadhospital
-
The Hague, Nederland, 2512 VA
- Medisch Centrum Haaglanden
-
-
-
-
-
Oslo, Noorwegen
- Oslo University Hospital
-
-
-
-
-
Lubin, Polen
- Miedziowe Centrum Zdrowia Lubin
-
Warsaw, Polen
- Centralny Szpital Kliniczny MSWiA w Warszawie
-
Warsaw, Polen
- Kliniki Kardiologii Allenort
-
Wroclaw, Polen
- 4 Wojskowy Szpital Kliniczny Z Poliklinika SP ZOZ
-
-
-
-
-
Singapore, Singapore, 308433
- Tan Tock Seng Hospital
-
Singapore, Singapore, 768828
- Khoo Teck Puat Hospital
-
-
-
-
-
Brno, Tsjechië
- University Hospital Brno
-
Hradec Králové, Tsjechië
- University Hospital Hradec Kralove
-
Liberec, Tsjechië
- Liberec Regional Hospital
-
-
-
-
-
Goteborg, Zweden, 41315
- Sahlgrenska Götheborg University Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in < 12 h after the onset of symptoms* and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.
- Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised
Exclusion Criteria:
- Left main stem disease (stenosis > 50%)
- STEMI due to in-stent thrombosis
- Chronic total occlusion of a non-IRA
- Severe stenosis with TIMI flow ≤ II of the non-IRA artery.
- Non-IRA stenosis not amenable for PCI treatment (operators decision)
Complicated IRA treatment, with one or more of the following;
- Extravasation,
- Permanent no re-flow after IRA treatment (TIMI flow 0-1),
- Inability to implant a stent
- Known severe cardiac valve dysfunction that will require surgery in the follow-up period.
- Killip class III or IV already at presentation or at the completion of culprit lesion treatment.
- Life expectancy of < 2 years.
- Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy.
- Gastrointestinal or genitourinary bleeding within the prior 3 months,
- Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
- Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
- Pregnancy or planning to become pregnant any time after enrolment into this study.
- Inability to obtain informed consent.
- Expected lost to follow-up.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: FFR-guided revascularisation strategy
In the FFR-group all flow limiting (FFR≤0.80)
lesions will receive treatment by PCI and stenting.
The non-IRA PCI should be performed during the same intervention.
Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload which may lead to deterioration of cardiac and renal function of the patient.
Such procedures can be performed in a second procedure which should take place within the same hospitalisation.
All lesions with a FFR measurement of >0.80 will not be treated.
|
FFR-guided revascularisation strategy
|
|
Placebo-vergelijker: randomised to guidelines group
In the randomised to guidelines group the procedure will stop after the FFR measurements and the patient will be referred to his treating cardiologist who will decide whether a staged PCI of the non-IRA artery should take place.
The treating cardiologist will be blinded for the FFR measurements (but not angiographic imaging) and must make a decision based on conventional non-invasive ischemia detecting tests or clinical signs and symptoms i.e. very typical angina symptoms in patients with angiographic significant stenosis).
|
Staged revascularisation by proven ischemia or persistence of symptoms of angina
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With the Composite Endpoint of MACCE
Tijdsspanne: 12 months
|
Number of participants with the composite endpoint of all cause mortality non-fatal Myocardial Infarction, any Revascularisation and Cerebrovascular Events (MACCE) at 12 months between groups
|
12 months
|
|
Number of Participants With Death From Any Cause
Tijdsspanne: 12 months
|
Number of participants with all cause mortality at 12 months between groups
|
12 months
|
|
Number of Participants With Cardiac Death
Tijdsspanne: 12 months
|
Number of participants with Cardiac mortality at 12 months between groups
|
12 months
|
|
Number of Participants With Spontaneous MI
Tijdsspanne: 12 months
|
Number of participants with Spontaneous Myocardial Infarction at 12 months between groups
|
12 months
|
|
Number of Participants With Periprocedural MI
Tijdsspanne: 12 months
|
Number of participants with Periprocedural Myocardial Infarction at 12 months between groups
|
12 months
|
|
Number of Participants With Revascularization - PCI
Tijdsspanne: 12 months
|
Number of participants with revascularization PCI at 12 months between groups
|
12 months
|
|
Number of Participants With Revascularization - CABG
Tijdsspanne: 12 months
|
Number of participants with revascularization CABG at 12 months between groups
|
12 months
|
|
Number of Participants With Cerebrovascular Event
Tijdsspanne: 12 months
|
Number of participants with Cerebrovascular event at 12 months between groups
|
12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of Participants With Composite Endpoint of NACE (Any First Event)
Tijdsspanne: 12 months
|
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 12 months (NACE i.e.
Net Adverse Clinical Events)
|
12 months
|
|
Number of Participants With Death From Any Cause or MI
Tijdsspanne: 12 months
|
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 12 months
|
12 months
|
|
Number of Participants With Major Bleeding
Tijdsspanne: 12 months
|
Number of participants with Major bleeding at 12 months - Part of composite NACE
|
12 months
|
|
Number of Participants With Any Bleeding at 12 Months
Tijdsspanne: 12 months
|
Number of participants with any bleeding at 12 months - part of composite endpoint NACE
|
12 months
|
|
Number of Participants With Any Bleeding at 48 Hours
Tijdsspanne: 48 hours
|
Number of participants with any bleeding at 48 hours - part of composite endpoint NACE
|
48 hours
|
|
Number of Participants With Hospitalization
Tijdsspanne: 12 months
|
Number of participants with hospitalization for heart failure, unstable angina or chest pain
|
12 months
|
|
Number of Participants With Revascularization
Tijdsspanne: 12 months
|
Number of participants with any revascularization-Part of composite endpoint NACE
|
12 months
|
|
Number of Participants With Stent Thrombosis
Tijdsspanne: 12 months
|
Number of participants with Stent Thrombosis - Part of composite endpoint NACE
|
12 months
|
|
Number of Participants With Primary Endpoint Outcome MACCE (Any First Event) at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite primary endpoint MACCE (any first event) at 3 year
|
3 year
|
|
Number of Participants With All Cause Death at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year - all cause death
|
3 year
|
|
Number of Participants With Cardiac Death at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Cardiac death
|
3 year
|
|
Number of Participants With Spontaneous MI at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Spontaneous MI
|
3 year
|
|
Number of Participants With Peri-procedural MI at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year - Peri-procedural MI
|
3 year
|
|
Number of Participants With Urgent Revascularization at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year - urgent revascularisation
|
3 year
|
|
Number of Participants With Elective Revascularization at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year -elective revascularisation
|
3 year
|
|
Number of Participants With Cerebrovascular Event
Tijdsspanne: 3 year
|
Number of participants with Composite endpoint MACCE (any first event) at 3 year -Cerebrovascular event
|
3 year
|
|
Number of Participants With Composite Endpoint of NACE (Any First Event) at 3 Year
Tijdsspanne: 3 years
|
Number of participants with Composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and Major bleeding at 3 year (NACE i.e.
Net Adverse Clinical Events)
|
3 years
|
|
Number of Participants With Death From Any Cause or MI
Tijdsspanne: 3 year
|
Number of participants with Part of composite NACE-Death from any cause or Myocardial Infarction at 3 year
|
3 year
|
|
Number of Participants With Major Bleeding at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Part of composite endpoint NACE- Major bleeding at 3 year
|
3 year
|
|
Number of Participants With Hospitalization
Tijdsspanne: 3 year
|
Number of participants with Hospitalization for heart failure, unstable angina, MI
|
3 year
|
|
Number of Participants With Hospitalization at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Hospitalization for heart failure, unstable angina, MI and/or chest pain
|
3 year
|
|
Number of Participants With Stent Thrombosis at 3 Year
Tijdsspanne: 3 year
|
Number of participants with Stent Thrombosis at 3 year - Part of composite endpoint NACE
|
3 year
|
|
Number of Participants With Any Bleeding at 3 Year
Tijdsspanne: 3 year
|
Number of participants with any bleeding at 3 year - Part of composite endpoint NACE
|
3 year
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
A Comparison of the Number of Patients in Both Groups With Treated Lesions With FFR ≤ 0.80 Versus Patients With Untreated Lesions With FFR ≤ 0.80;
Tijdsspanne: 3 year
|
FFR+/PCI+ vs FFR+/PCI- Comparison of patients having FFR positive lesions that underwent revascularization during index procedure or in staged procedures within 45 days (groups A+C, n=202 patients) with patients having FFR positive lesions that did not undergo revascularization (group D, n=231 patients),
|
3 year
|
|
Comparison of Acute Versus Staged PCI for Lesions With FFR ≤ 0.80
Tijdsspanne: 3 year
|
Comparison of acute versus staged PCI treatment for lesions with FFR
|
3 year
|
|
Comparison of PCI vs Medical Therapy in FFR Negative Lesions
Tijdsspanne: 3 year
|
comparison of patients receiving staged PCI treatment of FFR-negative lesions in the non-IRA (decision made by referring physician who was blinded to FFR results) and patients receiving medical therapy for FFR-negative lesions in the non-IRA
|
3 year
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Peter Smits, MD. PHD, Maastadhospital / MCR
- Studie stoel: Elmir Omerovic, MD PhD, Sahlgrenska Hospital Götheborg
- Studie stoel: Gert Richardt, MD PhD, Herzzentrum Segeberger Kliniken
- Studie stoel: Franz-Josef Neumann, MD PhD, Herz-Zentrum Bad Krozingen
Publicaties en nuttige links
Algemene publicaties
- Wang LJ, Han S, Zhang XH, Jin YZ. Fractional flow reserve-guided complete revascularization versus culprit-only revascularization in acute ST-segment elevation myocardial infarction and multi-vessel disease patients: a meta-analysis and systematic review. BMC Cardiovasc Disord. 2019 Mar 1;19(1):49. doi: 10.1186/s12872-019-1022-6.
- Piroth Z, Fulop G, Boxma-de Klerk BM, Abdelghani M, Omerovic E, Andreka P, Fontos G, Neumann FJ, Richardt G, Smits PC. Correlation and Relative Prognostic Value of Fractional Flow Reserve and Pd/Pa of Nonculprit Lesions in ST-Segment-Elevation Myocardial Infarction. Circ Cardiovasc Interv. 2022 Feb;15(2):e010796. doi: 10.1161/CIRCINTERVENTIONS.121.010796. Epub 2022 Jan 20.
- Smits PC, Abdel-Wahab M, Neumann FJ, Boxma-de Klerk BM, Lunde K, Schotborgh CE, Piroth Z, Horak D, Wlodarczak A, Ong PJ, Hambrecht R, Angeras O, Richardt G, Omerovic E; Compare-Acute Investigators. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med. 2017 Mar 30;376(13):1234-1244. doi: 10.1056/NEJMoa1701067. Epub 2017 Mar 18.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Compare-Acute
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .